Ignite Creation Date:
2024-05-06 @ 2:51 AM
Last Modification Date:
2024-10-26 @ 11:24 AM
Study NCT ID:
NCT02142803
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-01
First Post:
2014-05-16
Brief Title:
TORC12 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Stage IV Primary Peritoneal Cancer AJCC v7 |
| Adult Glioblastoma |
| Endometrial Clear Cell Adenocarcinoma |
| Endometrial Serous Adenocarcinoma |
| Ovarian Clear Cell Cystadenocarcinoma |
| Ovarian Endometrioid Adenocarcinoma |
| Ovarian Mucinous Cystadenocarcinoma |
| Ovarian Serous Cystadenocarcinoma |
| Recurrent Fallopian Tube Carcinoma |
| Recurrent Ovarian Carcinoma |
| Recurrent Primary Peritoneal Carcinoma |
| Recurrent Uterine Corpus Cancer |
| Solid Neoplasm |
| Stage IIIA Fallopian Tube Cancer AJCC v7 |
| Stage IIIA Ovarian Cancer AJCC v6 and v7 |
| Stage IIIA Primary Peritoneal Cancer AJCC v7 |
| Stage IIIB Fallopian Tube Cancer AJCC v7 |
| Stage IIIB Ovarian Cancer AJCC v6 and v7 |
| Stage IIIB Primary Peritoneal Cancer AJCC v7 |
| Stage IIIC Fallopian Tube Cancer AJCC v7 |
| Stage IIIC Ovarian Cancer AJCC v6 and v7 |
| Stage IIIC Primary Peritoneal Cancer AJCC v7 |
| Stage IV Fallopian Tube Cancer AJCC v6 and v7 |
| Stage IV Ovarian Cancer AJCC v6 and v7 |
Keywords: